News
)
15 November 2022
Successful participation of VIVEbiotech in international events in 2022
VIVEbiotech has successfully participated in 7 international events during 2023.
)
21 June 2022
VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck
VIVEbiotech, a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited new facility is now fully operational after receiving the renewal of its GMP accreditation for a further three years.
)
4 May 2022
Interview with Natalia Elizalde in The Medicine Maker
The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.
)
2 May 2022
Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022
The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List
Destacadas
)
September 18, 2024
Q&A in GEN with Natalia Elizalde)
September 11, 2024
VIVEbiotech participates in Advanced Therapies Europe)
September 9, 2024
VIVEbiotech achieves renewal of CIR certification)
August 28, 2024
New scientific paper in Viruses)
August 23, 2024
Enhancing global access to advanced therapies: VIVEbiotech’s role in optimizing production and reducing costs)
August 20, 2024
Exploring technological advances in CDMOs: insights in Pharma´s Almanac)
August 16, 2024
Natalia Elizalde discusses key trends from ASGCT 2024 annual meeting in Baltimore)
June 25, 2024
VIVEbiotech participates in a roundtable article in Pharma’s Almanac)
June 7, 2024
iMM Joins the MAGIC Consortium to Advance Research on Muscular Dystrophies)
May 31, 2024
VIVEbiotech receives the “New Company of Gipuzkoa 2024” award from ADEGI